Rising interest rates have raised concerns about the ability of biotechs to access capital. Contrary to popular perception, though, the sector is actually quite “healthy”, says portfolio manager Dr Bianca Ogden. Dedicated health funds are stepping in to provide support, while biotechs are refocusing and streamlining their product range, and there has been a flurry of mergers and acquisitions – as the sector prepares for the next chapter of growth.
The Platinum International Health Care Fund primarily invests in health care companies listed on securities markets around the world, and aims to provide capital growth over the long-term.
